FLT3 and acute myeloid leukemia: BCL-2 inhibitors navitoclax (Figure 4B) and venetoclax (Figure 4C) enhance chemotherapy and improve efficacy in patients with AML with an fms-like tyrosine kinase (FLT3) mutation (Stone et al., 2017).